About Fc receptor-like A
Fc receptor-like A (FCRLA) is a protein
from Homo sapiens identified by UniProt accession
Q7L513, 359 residues long.
MolForge cross-references it against 0 known binders and
126 disease associations.
Target properties
| Protein name | Fc receptor-like A |
| UniProt accession | Q7L513 |
| Gene | FCRLA |
| Organism | Homo sapiens |
| Length | 359 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (126)
Diseases linked to this target (Open Targets).
- lymphocyte count · score 0.37
- total blood protein measurement · score 0.36
- aspartate aminotransferase measurement · score 0.31
- blood protein measurement · score 0.29
- serum gamma-glutamyl transferase measurement · score 0.27
- erythrocyte count · score 0.27
- serum alanine aminotransferase measurement · score 0.23
- low affinity immunoglobulin gamma Fc region receptor II-a/b measurement · score 0.22
- alkaline phosphatase measurement · score 0.22
- albumin:globulin ratio measurement · score 0.19
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q7L513-F1 | alphafold | PREDICTED | 75.20 | — |
Amino-acid sequence (359 residues)
MKLGCVLMAW ALYLSLGVLW VAQMLLAASF ETLQCEGPVC TEESSCHTED DLTDAREAGF QVKAYTFSEP FHLIVSYDWL ILQGPAKPVF EGDLLVLRCQ AWQDWPLTQV TFYRDGSALG PPGPNREFSI TVVQKADSGH YHCSGIFQSP GPGIPETASV VAITVQELFP APILRAVPSA EPQAGSPMTL SCQTKLPLQR SAARLLFSFY KDGRIVQSRG LSSEFQIPTA SEDHSGSYWC EAATEDNQVW KQSPQLEIRV QGASSSAAPP TLNPAPQKSA APGTAPEEAP GPLPPPPTPS SEDPGFSSPL GMPDPHLYHQ MGLLLKHMQD VRVLLGHLLM ELRELSGHRK PGTTKATAE
Explore Fc receptor-like A with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets